EBRT Achieves Competitive Survival in Early HCC : J Clin Oncol | May 2026

Introduction

External Beam Radiation Therapy has historically played a limited role in the management of Hepatocellular Carcinoma because of concerns regarding radiation-induced liver injury and limited survival data. However, advances in image guidance, stereotactic body radiotherapy and conformal radiation delivery have substantially improved precision and safety. Despite increasing integration into treatment algorithms, robust multinational survival data supporting EBRT as a first-line curative-intent modality have remained limited.

Problem Statement

Although modern EBRT demonstrates excellent local tumor control in HCC, uncertainty persists regarding long-term survival outcomes compared with established curative therapies such as resection and thermal ablation. The absence of large individual patient-level datasets has limited broader incorporation of EBRT into global HCC treatment algorithms.

Summary

This multinational collaborative analysis evaluated individual patient data from 4,913 patients with HCC treated using technically validated EBRT protocols, representing the largest international EBRT cohort reported to date. Patients were stratified according to Barcelona Clinic Liver Cancer (BCLC) stage and prior treatment exposure to assess long-term overall survival outcomes.

Survival outcomes for very early- and early-stage HCC were particularly notable. Median overall survival reached 6.8 years for BCLC-0 disease and 4.6 years for BCLC-A disease. Among treatment-naïve patients, outcomes were even more impressive, with median survival not reached in BCLC-0 patients and exceeding five years in BCLC-A disease. These results compare favorably with many contemporary surgical and ablative series and strongly support EBRT as a potentially curative locoregional strategy in selected patients.

Multivariable analyses identified several prognostic determinants consistent with established HCC biology. Advanced BCLC stage, higher tumor burden, impaired performance status and Child-Pugh B/C cirrhosis independently predicted worse survival outcomes. Conversely, delivery of ablative radiation doses and treatment in more recent eras were associated with improved survival, likely reflecting ongoing technological advancements in radiation planning and patient selection.

Importantly, the study reinforces the evolving role of EBRT within multidisciplinary HCC management. Modern radiation therapy offers several advantages in patients unsuitable for surgery or thermal ablation, including treatment of lesions adjacent to vascular structures, biliary anatomy or subdiaphragmatic regions where ablative approaches may be technically difficult or high risk. The findings further challenge historical perceptions that radiation therapy should remain only a salvage or palliative modality in HCC.

The study additionally highlights the growing convergence between radiation oncology and hepatology within contemporary liver cancer care. Improved survival associated with ablative dosing strategies suggests that biologically effective dose escalation and stereotactic techniques may further optimize outcomes in early-stage disease.

Overall, this landmark multinational individual patient-level analysis provides strong evidence that modern EBRT achieves survival outcomes comparable to other curative locoregional therapies for selected early-stage HCC patients. The findings strongly support broader incorporation of EBRT into BCLC clinical decision-making pathways and reinforce its emerging role as a first-line treatment option within multidisciplinary hepatocellular carcinoma management.